Diagnostic Histopathology
Volume 15, Issue 3 , Pages 125-133 , March 2009

Diagnosis of chronic myeloproliferative neoplasms with special emphasis on early stages

References 

  1. Tefferi A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J. 2007;13:366–371
  2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–1097
  3. Smith CA, Fan G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol. 2008;39:795–810
  4. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272–4290
  5. Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol. 1975;12:409–432
  6. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29–39
  7. Pearson TC. Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol. 1998;11:695–720
  8. Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol. 2001;38:21–24
  9. Dickstein JI, Vardiman JW. Hematopathologic findings in the myeloproliferative disorders. Semin Oncol. 1995;22:355–373
  10. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev. 2001;15:121–131
  11. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol. 1999;36:9–13
  12. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954–2970
  13. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255–1265
  14. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45
  15. Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol. 2006;19:413–437
  16. Tefferi A, Vardiman JW. The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol. 2007;14:115–122
  17. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol. 1992;48:20–26
  18. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656–664
  19. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 1997;56:168–172
  20. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600 × 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol. 1998;100:15–23
  21. Sacchi S, Vinci G, Gugliotta L, et al. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600 × 10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC). Haematologica. 2000;85:492–495
  22. Buhr T, Buesche G, Choritz H, Langer F, Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol. 2003;119:152–158
  23. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med. 2003;139:470–475
  24. Thiele J, Kvasnicka HM, Schmitt-Gräff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma. 2003;44:549–553
  25. Thiele J, Kvasnicka HM. Prefibrotic chronic idiopathic myelofibrosis - a diagnostic enigma?. Acta Haematol. 2004;111:155–159
  26. Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the early prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol. 2008;130:336–342
  27. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93:1645–1651
  28. Nelson ME, Steensma DP. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?. Leuk Lymphoma. 2006;47:177–194
  29. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–3476
  30. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673–683
  31. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–468
  32. Najean Y, Triebel F, Dresch C. Pure erythrocytosis: reappraisal of a study of 51 cases. Am J Hematol. 1981;10:129–136
  33. Westwood N, Dudley JM, Sawyer B, Messinezy M, Pearson TC. Primary polycythaemia: diagnosis by non-conventional positive criteria. Eur J Haematol. 1993;51:228–232
  34. Messinezy M, Sawyer B, Westwood NB, Pearson TC. Idiopathic erythrocytosis - additional new study techniques suggest a heterogenous group. Eur J Haematol. 1994;53:163–167
  35. Pearson TC, Wetherley-Mein G. The course and complications of idiopathic erythrocytosis. Clin Lab Haematol. 1979;1:189–196
  36. Finazzi G, Gregg XT, Barbui T, Prchal JT. Idiopathic erythrocytosis and other non-clonal polycythemias. Best Pract Res Clin Haematol. 2006;19:471–482
  37. Tefferi A. The diagnosis of polycythemia vera: New tests and old dictums. Best Pract Res Clin Haematol. 2006;19:455–469
  38. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol. 2005;113:213–219
  39. Shih LY, Lee CT. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood. 1994;83:744–748
  40. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. Development of erythrocytosis in the course of essential thrombocythemia. Ann Hematol. 1999;78:219–222
  41. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol. 2005;20:317–328
  42. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica. 2001;86:368–374
  43. Everitt BS, Dunn G. Applied multivariate data analysis. London: Edward Arnold; 2001;
  44. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features - does it work in hematopathology for histological discrimination of different disease patterns?. Histol Histopathol. 2005;20:633–644
  45. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452–2466
  46. Messinezy M, Westwood NB, Woodcock SP, Strong RM, Pearson TC. Low serum erythropoietin - a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels. Clin Lab Haematol. 1995;17:217–220
  47. Carneskog J, Kutti J, Wadenvik H, Lundberg PA, Lindstedt G. Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol. 1998;60:278–282
  48. Birgegard G, Wide L. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol. 1992;81:603–606
  49. Eridani S, Sawyer B, Pearson TC. Patterns of in vitro BFU- E proliferation in different forms of polycythaemia and in thrombocythaemia. Eur J Haematol. 1987;38:363–369
  50. Partanen S, Juvonen E, Ikkala E, Ruutu T. Spontaneous erythroid colony formation in the differential diagnosis of erythrocytosis. Eur J Haematol. 1989;42:327–330
  51. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost. 1997;23:339–347
  52. Florena AM, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica. 2004;89:911–919
  53. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders - current diagnostic approach. Semin Hematol. 2005;42:184–195
  54. Gianelli U, Vener C, Raviele PR, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma. 2006;47:1774–1781
  55. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82:148–152
  56. Thiele J, Kvasnicka HM. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Thromb Hemost. 2006;32:219–230
  57. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract. 1993;189:121–132
  58. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol. 1998;11:721–749
  59. Buhr T, Georgii A, Schuppan O, Amor A, Kaloutsi V. Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts. Ann Hematol. 1992;64:286–291
  60. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma. 1999;33:207–218
  61. Bock O, Busche G, Koop C, Schroter S, Buhr T, Kreipe H. Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. J Mol Diagn. 2006;8:170–177
  62. Thiele J, Kvasnicka HM. Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol. 2005;32:380–394
  63. Thiele J, Zankovich R, Steinberg T, Fischer R, Diehl V. Agnogenic myeloid metaplasia (AMM) - correlation of bone marrow lesions with laboratory data: a longitudinal clinicopathological study on 114 patients. Hematol Oncol. 1989;7:327–343
  64. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol. 2001;80:160–165
  65. Kreft A, Buche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 2005;113:137–143
  66. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E. The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol. 1998;60:101–105
  67. Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood. 2008;111:1862–1865
  68. Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85:226–232
  69. Dingli D, Mesa RA, Tefferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med. 2004;43:540–547
  70. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31:737–740
  71. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437–438
  72. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005;353:85–86
  73. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32:362–371
  74. Barosi G, Ambrosetti A, Finelli C, et al. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol. 1999;104:730–737
  75. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma. 2006;47:381–396
  76. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol. 2002;70:283–291
  77. Bock O, Neuse J, Hussein K, et al. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol. 2006;169:471–481
  78. Bauermeister DE. Quantitation of bone marrow reticulin - a normal range. Am J Clin Pathol. 1971;56:24–31
  79. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43:185–190
  80. Thiele J, Kvasnicka HM, Facchetti F, Franco V, Van der Walt J, Orazi A. European consensus for grading of bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–1132
  81. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111:60–70
  82. Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features - a clinicopathological study on 272 patients. Histol Histopathol. 2003;18:93–102
  83. Dickstein JI, Vardiman JW. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am J Clin Pathol. 1993;99:513–525
  84. Thiele J, Kvasnicka HM. Myelofibrosis in chronic myeloproliferative disorders - dynamics and clinical impact. Histol Histopathol. 2006;21:1367–1378
  85. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22:905–914
  86. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997;80:708–719
  87. Strasser-Weippl K, Steurer M, Kees M, et al. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma. 2006;47:379–380
  88. Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109:2083–2088
  89. Cervantes F, Dupriez B, Pereira A, et al. A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2008 Nov 6;Epub ahead of print
  90. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112:231–239

PII: S1756-2317(09)00022-X

doi: 10.1016/j.mpdhp.2009.01.008

Diagnostic Histopathology
Volume 15, Issue 3 , Pages 125-133 , March 2009

Article Tools

* Image Usage & Resolution